Skip to main content
. 2021 Mar 1;41(2):145–154. doi: 10.3343/alm.2021.41.2.145

Table 3.

Characteristics of the 54 pediatric ALL patients

Characteristics Results
Male, N (%) 34 (63.0)
Age, median (IQR), years 6.5 (4.0-14.0)
Number of thiopurine metabolite measurements per patient, median (IQR) 4.5 (2.0-7.0)
TPMT genotype, N (%)
*1/*1 (normal metabolizer) 53 (98.1)
*1/*3C (intermediate metabolizer) 1 (1.9)
NUDT15 genotype, N (%)
*1/*1 (normal metabolizer) 43 (79.6)
*1/*2 (intermediate metabolizer) 5 (9.3)
*1/*3 (intermediate metabolizer) 2 (3.7)
*1/*5 (indeterminate phenotype) 2 (3.7)
*1/*6 (indeterminate phenotype) 2 (3.7)

TPMT and NUDT15 genotypes and phenotypes were evaluated according to the Clinical Pharmacogenetics Implementation Consortium guidelines [10, 28].

Abbreviations: ALL, acute lymphoblastic leukemia; IQR, interquartile range; TPMT, thiopurine S-methyltransferase.